tetano
Editor, Senior Moderator
J Infect Dev Ctries
. 2024 Feb 29;18(2):188-194.
doi: 10.3855/jidc.17927. A rare clinical presentation of COVID 19: opsoclonus-myoclonus ataxia syndrome
Adalet Altunsoy[SUP] 1 [/SUP], Nizamettin Kemirtlek[SUP] 2 [/SUP], Halime Araz[SUP] 2 [/SUP], Ebru Bilge Dirik[SUP] 3 [/SUP], Esragül Akıncı[SUP] 1 [/SUP]
Affiliations
Introduction: Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal.
Case presentation: We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey.
Discussion: OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.
Keywords: COVID-19; IVIG; corticosteroids; intravenous immunoglobulin; opsoclonus-myoclonus ataxia syndrome.
. 2024 Feb 29;18(2):188-194.
doi: 10.3855/jidc.17927. A rare clinical presentation of COVID 19: opsoclonus-myoclonus ataxia syndrome
Adalet Altunsoy[SUP] 1 [/SUP], Nizamettin Kemirtlek[SUP] 2 [/SUP], Halime Araz[SUP] 2 [/SUP], Ebru Bilge Dirik[SUP] 3 [/SUP], Esragül Akıncı[SUP] 1 [/SUP]
Affiliations
- PMID: 38484346
- DOI: 10.3855/jidc.17927
Introduction: Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal.
Case presentation: We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey.
Discussion: OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.
Keywords: COVID-19; IVIG; corticosteroids; intravenous immunoglobulin; opsoclonus-myoclonus ataxia syndrome.